Arecor wins at CambridgeshireLive Business Awards

RNS Number : 1371G

Arecor Therapeutics PLC

28 March 2022

ARECOR WINS INNOVATION IN BUSINESS AND BUSINESS PERSON OF THE YEAR AWARDS
AT THE CAMBRIDGESHIRELIVE BUSINESS AWARDS

Cambridge, UK, 28 March 2022: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, today announces that Arecor has won the HCR Hewitsons Award for Innovation in Business, and CEO, Sarah Howell, has won Business Person of the Year at the UK CambridgeshireLive Business Awards.

The CambridgeshireLive Business Awards celebrate and recognise the region's best business talent, providing companies of all sizes, from pioneering start-ups to the powerhouses which drive the region's economy a chance to be recognised and be proud of their achievements.

Sarah Howell, Chief Executive Officer of Arecor, said: "We are delighted to have won the Award for Innovation in Business, and I am honoured to be recognised amongst such high-quality candidates leading innovative and dynamic companies in Cambridge. Innovation is at the heart of everything we do here at Arecor as we develop new advanced medicines from today's therapies to improve the lives of patients. These awards are an important external validation of Arecor's strengths and will support us to attract scientific talent to our growing business."

-ENDS-

For more information, please contact:

Arecor Therapeutics plc	www.arecor.com
Dr Sarah Howell, Chief Executive Officer	Tel: +44 (0) 1223 426060 Email: [email protected]

Susan Lowther, Chief Financial Officer	Tel: +44 (0) 1223 426060 Email: [email protected]

Mo Noonan, Communications	Tel: +44 (0) 7876 444977 Email: [email protected]

Panmure Gordon (UK) Limited (NOMAD and Broker) Freddy Crossley, Emma Earl (Corporate Finance) Rupert Dearden (Corporate Broking)	Tel: +44 (0) 20 7886 2500

Consilium Strategic Communications
Chris Gardner, David Daley, Angela Gray	Tel: +44 (0) 20 3709 5700 Email: [email protected]

Notes to Editors

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical group transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio.

For further details please see our website, www.arecor.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAEAXDSADDAEFA